Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) EBITDA Margin (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed EBITDA Margin for 3 consecutive years, with 233656.25% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 23293489.0% to 233656.25% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 904.29% through Dec 2025, down 37414.0% year-over-year, with the annual reading at 904.29% for FY2025, 37414.0% down from the prior year.
  • EBITDA Margin hit 233656.25% in Q4 2025 for NewAmsterdam Pharma, down from 20601.15% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 57.18% in Q3 2024 to a low of 233656.25% in Q4 2025.
  • Historically, EBITDA Margin has averaged 22945.29% across 3 years, with a median of 1657.1% in 2023.
  • Biggest five-year swings in EBITDA Margin: surged 544240bps in 2024 and later crashed -23293489bps in 2025.
  • Year by year, EBITDA Margin stood at 6163.76% in 2023, then soared by 88bps to 721.36% in 2024, then tumbled by -32291bps to 233656.25% in 2025.
  • Business Quant data shows EBITDA Margin for NAMS at 233656.25% in Q4 2025, 20601.15% in Q3 2025, and 91.26% in Q2 2025.